Bristol Myers Squibb reports positive phase 3 results for myeloma drug

March 9, 2026 6:59 AM

Bristol Myers Squibb (NYSE: BMY) reported positive interim Phase 3 results from its SUCCESSOR-2 study of oral mezigdomide in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found